Therapeutic approach to dyslipidemia and goal achievement in a spanish population with type 2 diabetes without cardiovascular disease;Estrategia de tratamiento de la dislipemia y consecucio n de objetivos en la poblacion española con diabetes tipo 2 sin enfermedad cardiovascular

Endocrinologia y Nutricion

Volumn 58, Issue 6, 2011, Pages 283-290

  Pérez, Antonio ^a,b   González Blanco, Cintia ^a,c   Hernández Presa, Miguel Ángel ^b   Chaves, José ^d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d PFIZER INC   (United States)

Author keywords

Cardiovascular risk; Dyslipidemia; Lipid goals; Lipid lowering drugs; Type 2 diabetes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALBUMINURIA; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; DISEASE CONTROL; DISEASE DURATION; DRUG MEGADOSE; DRUG POTENCY; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIMARY MEDICAL CARE; RETINOPATHY; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTHROPOMETRY; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GOALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SAMPLING STUDIES; SMOKING; SPAIN; TREATMENT OUTCOME;

EID: 79960417491     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2011.03.005     Document Type: Article

References (45)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
2. Golf D.C., Gerstein H.C., Ginnsberg H.N., Cushman W.C., Margolis K.L., Byington R.P., et al. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current Knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. AM J Cardiol 2007, 99:4i-20i. ACCORD Study Group.
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s). Lancet 1994, 344:1383-1389. Scandinavian Simvastatin Survival Study Group.
4. Sacks F.M., TonKin A.M., Craven T., Pfeffer M.A., Shepherd J., Keech A., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin pooling Project. Circulation 2002, 105:1424-1428.
5. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016. Heart Protection Study Collaborative Group.
6. Gaede P., Vedel P., Larsen N., Jensen G.V.H., Parving H.H., Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
7. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.
8. Turner R.C., Millns H., Neill H.A.W., Stratton I.M., Matthews D.R., Holman R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ 1998, 316:823-828. for the United Kingdom Prospective Diabetes Study Group.
9. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart protection Study Collaborative Group.
10. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaboratuve Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696. on behalf of the CARDS investigators.
11. Lewis S.J., Moye L.A., Sacks F.M., Johnstone D.E., Timmis G., Mitchell J., et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and recurrent Events (CARE) trial. Ann Intern Med 1998, 129:681-689.
12. Goldberg R.B., Mellies M.J., Sacks F.M., Moyé L.A., Howard B.V., Howard V.J., et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and recurrent Events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513-2519.
13. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
14. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER: Arterial Biology for the investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravstatin on carotid intima medial thickness. Circulation 2002, 106:2055-2060.
15. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., Grace K.A. Arterial Biology for the investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind placebo-controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512-3517.
16. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
17. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 3 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
18. Turner R.C., Millns H., Neil H.A., Stratton I.M., Manley S.E., Matthews D.R., et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
19. Leiter L.A., Betteridge J., Chacra A.R., Chait A., Ferrannini E., Haffner S.M., et al. AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2006, 6:31-40. on behalf of the AUDIT Study Steering Committee.
20. García Ruiz F.J., Marín Ibáñez A., Pérez-Jiménez F., Pinto X., Nocea G., Ahumada C., et al. The REALITY Study. Pharmacoeconomics 2004, 22(Suppl 3):S1-12. REALITY Study Group.
21. Van Ganse E., Laforest L., Alemao E., Davies G., Gutkin S., Yin D. Lipid modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005, 21:1389-1399.
22. Díaz de Rojas F., De Frutos T., Ponte A., Mateos Chacón J., Vitale G.C. Coronary Heart Disease and Dyslipidemia: A Cross-Sectional Evaluation of Prevalence, Current Treatment, and Clinical Control in a Large Cohort of Spanish High-Risk Patients: The PRINCEPS Study. Prev Cardiol 2009, 12:65-71. for the PRINCEPS Investigators.
23. de la Peña Fernández A., Roca Villanueva B., Cuende Melero I., Calabuig Alborch J.R., Montes Santiago J., Muñoz Rodríguez M., et al. Effect of a global intervention in the integral control of multiple risk factors in patients at high or very high cardiovascular risk. CIFARC 2 project. Rev Clin Esp 2007, 203:112-120.
24. Lahoz-Rallo B., Blanco-González M., Casas-Ciria I., Marín-Andrade J.A., Méndez-Segovia J.C., Moratalla-Rodríguez G., et al. Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. Diabetes Res Clin Pract 2007, 76:436-444.
25. Kearney P.M., Blackwell L., Collins R., Keech A., Simes J., Peto R., et al. Efficacy of cholesterol-lowering treatment in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. Cholesterol Treatment Trialists' (CTT) Collaborators.
26. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
27. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., et al. Effect of lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients with Coronary Heart Diseaseand Diabetes. The Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
28. Thomas R.J., Palumbo P.J., Melton L.J., Roger V.L., Ransom J., O'Brien P.C., et al. Trends in the mortality burden associated with diabetes mellitus: a population-based study in Rochester, Minn, 1970-1994. Arch Intern Med 2003, 163:445-451.
29. Kotseva K., Wood D., De Backer G., De Bacquer D., Pyörälä K., Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009, 373:929-940. EUROASPIRE Study Group.
30. Álvarez-Sala L., Suárez C., Mantilla T., Franch J., Ruilope L.M., Banegas J.R., et al. Estudio PREVENCAT: control de los factores de riesgo cardiovascular en Atención Primaria. Med Clin (Barc) 2005, 124:406-410.
31. Eficacia del control de los factores de riesgo cardiovascular en la población con diabetes tipo 2 de la provincia de Ciudad Real. Rev Clin Esp 2005, 205:218-222. Grupo ECLIPSE.
32. De la Peña A., Suárez C., Cuende I., Muñoz M., Garre J., Camafort M., et al. Control integral de los factores de riesgo cardiovascular en pacientes de alto y muy alto riesgo cardiovascular en España. Proyecto CIFARC. Med Clin (Barc) 2005, 124:44-49.
33. Mann D.M., Allegrante J.P., Natarajan S., Halm E.A., Charlson M. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007, 21:311-316.
34. Casebeer L., Huber C., Bennett N., Shillman R., Abdolrasulnia M., Salinas G.D., et al. Improving the physician-patient cardiovascular risk dialogue to improve statin adherence. BMC Fam Pract 2009, 10:48.
35. Hsu W.C. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J 2009, 102:67-76.
36. Krobot K.J., Yin D.D., Alemao E., Steinhagen-Thiessen E. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors. Eur J Cardiovasc Prev Rehabil 2005, 12:37-45.
37. Walters D.D. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005, 96:69F-75F.
38. Athyros V.G., Papageorgou A.A., Merouris B.R., Athyrou V.V., Symeonidis A.N., Basayannis E.O., et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary heart disease prevention: the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002, 18:220-228.
39. Leiter L.A., Martineau P., de Teresa E., Farsang C., Gaw A., Gensini G., et al. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. J Fam Pract 2008, 57:661-668.
40. Alagona P. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care 2009, 15:S65-S73.
41. Barter P.J., Gotto A.M., LaRosa J.C., Maroni J., Szarek M., Grundy S.M., et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301-1310.
42. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braundwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730. PROVE IT-TIMI 22 Investigators.
43. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822. American Diabetes Association; American College of Cardiology Foundation.
44. Fruchart J.C., Sacks F.M., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102(Suppl):1K-34K.
45. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., Ahearn D., Kuvin J.T., Karas R.H. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006, 98:1231-1233.